XTX Topco Ltd Takes $673,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

XTX Topco Ltd acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,805 shares of the company's stock, valued at approximately $673,000.

Several other large investors have also modified their holdings of the business. Checchi Capital Advisers LLC purchased a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $202,000. BLB&B Advisors LLC grew its holdings in shares of Ionis Pharmaceuticals by 5.2% in the second quarter. BLB&B Advisors LLC now owns 153,750 shares of the company's stock valued at $7,328,000 after purchasing an additional 7,650 shares during the period. Peregrine Capital Management LLC boosted its stake in Ionis Pharmaceuticals by 11.3% during the second quarter. Peregrine Capital Management LLC now owns 132,024 shares of the company's stock worth $6,292,000 after buying an additional 13,426 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 27.6% in the second quarter. International Assets Investment Management LLC now owns 9,707 shares of the company's stock valued at $463,000 after purchasing an additional 2,100 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Ionis Pharmaceuticals by 3.2% in the second quarter. Commonwealth Equity Services LLC now owns 22,669 shares of the company's stock valued at $1,080,000 after purchasing an additional 695 shares during the period. Institutional investors own 93.86% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a report on Thursday, November 7th. Guggenheim decreased their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, October 9th. Piper Sandler cut their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. boosted their target price on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Monday, August 26th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $60.65.

Insiders Place Their Bets

In other news, EVP Eric Swayze sold 1,194 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now directly owns 33,713 shares of the company's stock, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 6,630 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares of the company's stock, valued at $6,369,303.65. This trade represents a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,877 shares of company stock valued at $299,578. Corporate insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Stock Performance

IONS traded down $0.40 during midday trading on Friday, hitting $36.61. 1,070,407 shares of the company were exchanged, compared to its average volume of 1,333,200. Ionis Pharmaceuticals, Inc. has a 1-year low of $33.33 and a 1-year high of $54.44. The firm's 50 day moving average price is $37.54 and its 200-day moving average price is $42.29. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.